

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7219359

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
JANSSEN BIOTECH, INC.		03/09/2022
RECEIVING PARTY DATA		
Name:	MOMENTA PHARMACEUTICALS, INC.	
Street Address:	1125 TRENTON-HARBOURTON ROAD	
City:	TITUSVILLE	
State/Country:	NEW JERSEY	
Postal Code:	08560	
PROPERTY NUMBERS Total: 65		
Property Type	Number	
Application Number:	16363846	
Application Number:	17407814	
Application Number:	16303831	
Application Number:	16303793	
Application Number:	17491677	
Application Number:	15141413	
Application Number:	61987863	
Application Number:	62081923	
PCT Number:	US2015028926	
Application Number:	62340322	
Application Number:	62443451	
Application Number:	62443495	
Application Number:	62510228	
Application Number:	62589473	
PCT Number:	US2018012488	
Application Number:	17259051	
Application Number:	17259061	
Application Number:	17259491	
Application Number:	17259067	
Application Number:	17527741	

Property Type	Number
Application Number:	14416869
Application Number:	15957703
Application Number:	17508026
PCT Number:	US2021033150
Application Number:	17403278
Application Number:	16081829
Application Number:	62302419
PCT Number:	US2021033156
Application Number:	15954146
Application Number:	16589634
Application Number:	17602156
Application Number:	63116643
PCT Number:	US2021060182
Application Number:	61768027
Application Number:	61676253
Application Number:	17032994
Application Number:	17033452
Application Number:	17100428
Application Number:	14787403
Application Number:	61818563
Application Number:	16671595
Application Number:	14890865
Application Number:	61822795
Application Number:	15985288
Application Number:	16688772
Application Number:	15028917
Application Number:	61891778
Application Number:	62744536
Application Number:	62879930
PCT Number:	US2019055983
PCT Number:	US2019055987
Application Number:	62836016
Application Number:	62985381
Application Number:	63026826
Application Number:	63108741
Application Number:	62981293
Application Number:	63026927
PCT Number:	US2021019607

Property Type	Number
Application Number:	62986144
Application Number:	63026875
Application Number:	62985467
Application Number:	63026805
PCT Number:	US2021020898
Application Number:	63068098
Application Number:	63068796

CORRESPONDENCE DATA

Fax Number: (877)769-7945

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: +1 (617) 368-2139

Email: apsi@fr.com

Correspondent Name: KATIE HYMA

Address Line 1: FISH & RICHARDSON P.C.

Address Line 2: P.O.BOX 1022

Address Line 4: MINNEAPOLIS, MINNESOTA 55440-1022

ATTORNEY DOCKET NUMBER:	14131-0001001
NAME OF SUBMITTER:	RITA M. LISTON
SIGNATURE:	/Rita M. Liston/
DATE SIGNED:	03/11/2022

Total Attachments: 10

source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page1.tif
source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page2.tif
source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page3.tif
source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page4.tif
source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page5.tif
source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page6.tif
source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page7.tif
source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page8.tif
source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page9.tif
source=14131_Jenssen_Momenta_AssignmentJBIttoMPI#page10.tif

ASSIGNMENT

Assignor: Janssen Biotech, Inc.
a corporation organized and existing under the laws of Pennsylvania, and having a
place of business at:
800/850 Ridgeview Drive
Horsbarn, PA 19044

Assignee: Momenta Pharmaceuticals, Inc.
a corporation organized and existing under the laws of Delaware, and having a place
of business at:
1125 Trenton-Harbourton Road
Titusville, NJ 08560

As included on the attached Schedule A and Schedule B documents:

1. Assignor represents that it is the owner of the patents and patent applications listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in Assignee's name wherever so permitted by law or in the name of Assignor wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to any of the Patents and Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes.
3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the


Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.

4. Assignor hereby assigns to Assignee (a) all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications and (b) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Patent Assets, and any other rights assigned by this Assignment.
5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.
6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.
7. To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous assignment.
8. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

The Assignor hereby executes this Assignment.

Assignor: Janssen Biotech, Inc.


Signature: 

Date: 3/9/22

Name: Melissa Miller


Title: Assistant Secretary, Janssen Biotech, Inc.

Witnessed by:

Signature: 

Date: 3/9/2022

Print Name: Lynn Morozin

Signature: 

Date: 3/9/2022

Print Name: Helene L. Hill

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: Momenta Pharmaceuticals, Inc.

Signature: Melissa Miller

Date: 3/9/22

Name: Melissa Miller

Title: Momenta Pharmaceuticals, Inc.

Witnessed by:

Signature: Lynn Morozin

Date: 3/9/2022

Print Name: Lynn Morozin

Signature: Helene L. Hill

Date: 3/9/2022

Print Name: Helene L. Hill

SCHEDULE A

Country	Filed Date	Serial #	Title
US	3/25/2019	16/363,846	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	8/20/2021	17/407,814	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	11/21/2018	16/303,831	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	11/21/2018	16/303,793	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	10/1/2021	17/491,677	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
AU	5/1/2015	2015252866	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR	5/1/2015	112016024780-9	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
CA	5/1/2015	2941072	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
CN	5/1/2015	201580020385.0	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
EP	5/1/2015	15785583.4	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
HK	5/1/2015	17102540.2	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
IL	5/1/2015	274735	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
IL	5/1/2015	247442	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
IN	5/1/2015	201637028929	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
JP	5/1/2015	2020-084900	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
JP	5/1/2015	2016564612	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
KR	5/1/2015	10-2016-7029772	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
NZ	5/1/2015	724375	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
SG	5/1/2015	102019135075	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
SG	5/1/2015	11201607070V	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	4/28/2016	15/141413	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	5/2/2014	61/987863	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	11/19/2014	62/081923	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WO	5/1/2015	PCT/US2015/028926	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
AU	5/23/2017	2017272111	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
AU	5/23/2017	2017272109	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR	5/23/2017	112018074032-2	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS

BR	5/23/2017	1120180740560	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
CA	5/23/2017	3025310	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
CA	5/23/2017	3025306	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
CN	5/23/2017	201780045688.7	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
CN	5/23/2017	201780045710.8	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
EP	5/23/2017	17803465.8	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
EP	5/23/2017	17803463.3	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
HK	5/23/2017	19129499	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
HK	5/23/2017	19129500.5	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
IL	5/23/2017	263211	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
IL	5/23/2017	263213	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
IN	5/23/2017	201817048464	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
IN	5/23/2017	201817048201	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
JP	5/23/2017	2018561639	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
JP	5/23/2017	2018561641	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
KR	5/23/2017	1020187037345	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
KR	5/23/2017	1020187037334	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
NZ	5/23/2017	749279	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
NZ	5/23/2017	749292	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
SG	5/23/2017	102020116245	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
SG	5/23/2017	11201810465R	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
SG	5/23/2017	11201810466P	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
US	5/23/2017	16/303831	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
US	5/23/2017	16/303793	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
US	5/23/2016	62/340322	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
US	1/6/2017	62/443451	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
WO	5/23/2017	PCT/US2017/034087	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
WO	5/23/2017	PCT/US2017/034084	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS
AU	1/5/2018	2018205808	COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS

BR	1/5/2018	112019013955-9	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
CA	1/5/2018	3049383	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
CN	1/5/2018	201880016496.8	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
EP	1/5/2018	18736414.6	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
HK	1/5/2018	62020006479	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
IN	1/5/2018	201937030485	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
JP	1/5/2018	2019537119	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
KR	1/5/2018	1020197023075	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
RU	1/5/2018	2019124710	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
SG	1/5/2018	11201906133V	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	1/6/2017	62/443495	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	5/23/2017	62/510228	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	11/21/2017	62/589473	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WO	1/5/2018	PCT/US2018/012488	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	1/8/2021	17/259,051	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc ANTIGEN BINDING DOMAIN CONSTRUCTS
US	1/8/2021	17/259,061	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CCR4
US	1/11/2021	17/259,491	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
US	1/8/2021	17/259,067	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
US	5/28/2019	16/474,640	ENGINEERED Fc CONSTRUCTS
US	11/16/2021	17/527,741	ENGINEERED Fc CONSTRUCTS
US	1/23/2015	14/416,869	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
US	4/19/2018	15/957,703	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
US	4/19/2018	17/508,026	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
US	10/22/2021	17/508,026	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
WIPO	5/19/2021	PCT/US2021/033150	HYPER-SIALYLATED IMMUNOGLOBULIN
US	8/16/2021	17/403,278	METHODS FOR MEASURING CONSUMPTION OF AMINO ACID N-CARBOXYANHYDRIDES DURING MANUFACTURE OF GLATIRAMER ACETATE
US	8/31/2018	16/081,829	METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
EP	3/2/2017	17760849.4	METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	3/2/2016	62/302419	METHODS RELATED TO ENGINEERED Fc CONSTRUCTS

WO	3/2/2017	PCT/US2017/020519	METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WIPO	5/19/2021	PCT/US2021/033156	PREPARATION AND PURIFICATION OF HYPERSIALYLATED IgG
US	4/16/2018	15/954,146	SIALYLATED GLYCOPROTEINS
US	10/1/2019	16/589,634	SIALYLATED GLYCOPROTEINS
US	10/7/2021	17/602,156	SIALYLATED GLYCOPROTEINS
US	11/20/2020	63/116,643	SIALYLATED GLYCOPROTEINS
WIPO	11/19/2021	PCT/US2021/060182	SIALYLATED GLYCOPROTEINS
US	5/2/2014	61/987,863	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	11/19/2014	62/081,923	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	5/23/2016	62/340,322	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	1/6/2017	62/443,451	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	1/6/2017	62/443,495	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	5/23/2017	62/510,228	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	11/21/2017	62/589,473	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US	7/26/2012	61/768,027	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES

SCHEDULE B

Country	Filing Number	Filing Dates	Title
EP	13822833.3	25 Jul 2013	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
US	15/957703	19 Apr 2018	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
US	14/416869	25 Jul 2013	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
US	61/676253	26 Jul 2012	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
US	61/768027	22 Feb 2013	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
WO	PCT/US2013/052040	25 Jul 2013	GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
DE	14792116.7	01 May 2014	SIALYLATED GLYCOPROTEINS
EP	14792116.7	01 May 2014	SIALYLATED GLYCOPROTEINS
EP	20158041.2	01 May 2014	SIALYLATED GLYCOPROTEINS
ES	14792116.7	01 May 2014	SIALYLATED GLYCOPROTEINS
FR	14792116.7	01 May 2014	SIALYLATED GLYCOPROTEINS
GB	14792116.7	01 May 2014	SIALYLATED GLYCOPROTEINS
HK	16109867.3	01 May 2014	SIALYLATED GLYCOPROTEINS
HK	42021025449	03 Feb 2021	SIALYLATED GLYCOPROTEINS
IE	14792116.7	01 May 2014	SIALYLATED GLYCOPROTEINS
IS	14792116.7	01 May 2014	SIALYLATED GLYCOPROTEINS
IT	14792116.7	01 May 2014	SIALYLATED GLYCOPROTEINS
NL	14792116.7	01 May 2014	SIALYLATED GLYCOPROTEINS
US	15/954146	16 Apr 2018	SIALYLATED GLYCOPROTEINS
US	16/589634	01 Oct 2019	SIALYLATED GLYCOPROTEINS
US	17/032994	25 Sep 2020	SIALYLATED GLYCOPROTEINS
US	17/033452	25 Sep 2020	SIALYLATED GLYCOPROTEINS
US	17/100428	20 Nov 2020	SIALYLATED GLYCOPROTEINS
US	14/787403	01 May 2014	SIALYLATED GLYCOPROTEINS
US	61/818563	02 May 2013	SIALYLATED GLYCOPROTEINS
WO	PCT/US2014/036413	01 May 2014	SIALYLATED GLYCOPROTEINS
DE	14798473.6	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
EP	14798473.6	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
ES	14798473.6	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
FR	14798473.6	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
GB	14798473.6	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
HK	16109873.5	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
IS	14798473.6	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
IT	14798473.6	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
NL	14798473.6	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
US	16/671595	01 Nov 2019	METHODS FOR THE TREATMENT OF NEURODEGENERATION
US	14/890865	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
US	61/822795	13 May 2013	METHODS FOR THE TREATMENT OF NEURODEGENERATION
WO	PCT/US2014/037761	13 May 2014	METHODS FOR THE TREATMENT OF NEURODEGENERATION
EP	14853244.3	14 Oct 2014	SIALYLATED GLYCOPROTEINS

Country	Filing Number	Filing Dates	Title
HK	17101752.7	14 Oct 2014	SIALYLATED GLYCOPROTEINS
US	15/985288	21 May 2018	SIALYLATED GLYCOPROTEINS
US	16/688772	19 Nov 2019	SIALYLATED GLYCOPROTEINS
US	15/028917	14 Oct 2014	SIALYLATED GLYCOPROTEINS
US	61/891778	16 Oct 2013	SIALYLATED GLYCOPROTEINS
WO	PCT/US2014/060363	14 Oct 2014	SIALYLATED GLYCOPROTEINS
AU	2019357842	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
BR	BR 11 2021 006852-0	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
CA	3,115,821	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
CN	2.0198E+11	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
EA	202190875	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
EP	19872100.3	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
IL	282136	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
JP	2021-519701	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
KR	10-2021-7013913	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
US	17/284188	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
US	17/284,188	4/9/2021	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
US	62/744536	11 Oct 2018	HYPER-SIALYLATED IVIG
US	62/879930	29 Jul 2019	HYPER-SIALYLATED IVIG
WO	PCT/US2019/055983	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
WO	PCT/US2019/055987	11 Oct 2019	TREATMENT WITH HIGHLY SIALYLATED IgG COMPOSITIONS
US	62/836016	18 Apr 2019	SIALYLATED GLYCOPROTEINS
WO	PCT/US2020/028863	17 Apr 2020	SIALYLATED GLYCOPROTEINS
US	62/985381	05 Mar 2020	HYPER-SIALYLATED IMMUNOGLOBULIN
US	63/026826	19 May 2020	HYPER-SIALYLATED IMMUNOGLOBULIN
US	63/108741	02 Nov 2020	HYPER-SIALYLATED IMMUNOGLOBULIN
US	62/981293	25 Feb 2020	ENZYME FOR SIALYLATION OF GLYCANS
US	63/026927	19 May 2020	ENZYME FOR SIALYLATION OF GLYCANS
WO	PCT/US2021/019607	25 Feb 2021	ENZYME FOR SIALYLATION OF GLYCANS
US	62/986144	06 Mar 2020	PREPARATION AND PURIFICATION OF HYPER-SIALYLATED IgG
US	63/026875	19 May 2020	PREPARATION AND PURIFICATION OF HYPER-SIALYLATED IgG
US	62/985467	05 Mar 2020	METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN
US	63/026805	19 May 2020	METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN
WO	PCT/US2021/020898	04 Mar 2021	METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN
US	63/068098	20 Aug 2020	SIALYLATED GLYCOPROTEINS
US	63/068796	21 Aug 2020	HYPER-SIALYLATED IMMUNOGLOBULIN

PATENT

RECORDED: 03/11/2022

REEL: 059595 FRAME: 0335